Saman Hewamana

Summary

Affiliation: Cardiff University
Country: UK

Publications

  1. ncbi IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Int J Hematol 88:424-7. 2008
  2. ncbi Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
    Clin Exp Nephrol 13:179-81. 2009
  3. ncbi The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Clin Cancer Res 14:8102-11. 2008
  4. ncbi The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib
    Elisabeth J Walsby
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Mol Cancer Ther 9:1574-82. 2010
  5. ncbi Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom
    J Clin Oncol 27:763-9. 2009
  6. ncbi Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis
    Thet Thet Lin
    Department of Pathology, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom
    Blood 116:1899-907. 2010
  7. ncbi Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia
    Christopher Jenkins
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Br J Haematol 143:661-71. 2008
  8. ncbi Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient
    Thet Thet Lin
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Br J Haematol 142:595-605. 2008
  9. ncbi Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
    Chris Pepper
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 112:3807-17. 2008
  10. ncbi Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38
    Laurence Pearce
    Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, UK
    Haematologica 95:514-7. 2010

Collaborators

Detail Information

Publications16

  1. ncbi IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Int J Hematol 88:424-7. 2008
    ..This case highlights the value of detailed immunophenotypic evaluation when clinical and morphological markers are equivocal...
  2. ncbi Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
    Clin Exp Nephrol 13:179-81. 2009
    ..Leukaemic infiltration of kidney should always be considered when a patient with CLL presents with renal impairment, regardless of the clinical stage, as the renal failure often responds well to chemotherapy...
  3. ncbi The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Clin Cancer Res 14:8102-11. 2008
    ..Here we elucidated the mechanism of action of LC-1, evaluated its relative cytotoxicity in prognostic subsets, and investigated its potential synergistic interaction with fludarabine...
  4. ncbi The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib
    Elisabeth J Walsby
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Mol Cancer Ther 9:1574-82. 2010
    ..Furthermore, LC-1-induced transcriptional suppression of survivin and MCL1 provides a potential explanation for its synergy with conventional agents...
  5. ncbi Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom
    J Clin Oncol 27:763-9. 2009
    ..We recently demonstrated the biologic importance of the nuclear factor kappa B (NF-kappaB) subunit Rel A in chronic lymphocytic leukemia (CLL) and hypothesized that Rel A DNA binding would have prognostic significance in this disease...
  6. ncbi Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis
    Thet Thet Lin
    Department of Pathology, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom
    Blood 116:1899-907. 2010
    ..Taken together, our data support the concept that telomere erosion and subsequent telomere fusion are critical in the progression of CLL and that this paradigm may extend to other malignancies...
  7. ncbi Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia
    Christopher Jenkins
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Br J Haematol 143:661-71. 2008
    ..Importantly, sensitivity to LC-1 was correlated with the basal NF-kappaB activity. Consequently, LC-1 treatment provides a proof of principle for the use of NF-kappaB inhibitors in the treatment of AML...
  8. ncbi Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient
    Thet Thet Lin
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Br J Haematol 142:595-605. 2008
    ....
  9. ncbi Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
    Chris Pepper
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 112:3807-17. 2008
    ..The close correlation between Mcl-1 expression and V(H) gene mutation status, CD38 expression, and ZAP-70 expression offers a biologic explanation for their association with adverse prognosis...
  10. ncbi Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38
    Laurence Pearce
    Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, UK
    Haematologica 95:514-7. 2010
    ..This high level of transduction of all the CLL cell samples tested demonstrates the utility of this technique which should prove applicable for the introduction and analysis of other genes in these non-dividing cells...
  11. ncbi NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia
    Chris Pepper
    School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
    Future Oncol 5:1027-37. 2009
    ....
  12. ncbi Defining the prognosis of early stage chronic lymphocytic leukaemia patients
    Chris Pepper
    School of Medicine, Cardiff University, Cardiff, UK
    Br J Haematol 156:499-507. 2012
    ..ZAP-70 expression and FISH were not independent prognostic markers in early stage disease and can be omitted at diagnosis but FISH analysis should be undertaken at disease progression to direct treatment strategy...
  13. ncbi Targeting transcription factors for therapeutic benefit
    Paul Brennan
    Medical Biochemistry and Immunology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Mol Biosyst 4:909-19. 2008
    ..This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of cancer...
  14. ncbi Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia
    Christopher Jenkins
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Leuk Res 35:677-81. 2011
    ....
  15. ncbi The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 111:4681-9. 2008
    ..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease...
  16. ncbi Examination of the bone marrow
    Christopher Jenkins
    Department of Haematology, Cardiff University, Cardiff CF14 4XN
    Br J Hosp Med (Lond) 69:M124-7. 2008